Quest Capital Management Inc. ADV lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 98.9% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 863 shares of the medical research company’s stock after selling 74,887 shares during the quarter. Quest Capital Management Inc. ADV’s holdings in Thermo Fisher Scientific were worth $253,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Dimensional Fund Advisors LP grew its holdings in Thermo Fisher Scientific by 0.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,706,326 shares of the medical research company’s stock valued at $605,651,000 after purchasing an additional 17,860 shares during the period. Meeder Asset Management Inc. grew its holdings in Thermo Fisher Scientific by 73.2% during the first quarter. Meeder Asset Management Inc. now owns 1,237 shares of the medical research company’s stock valued at $338,000 after purchasing an additional 523 shares during the period. Pennsylvania Trust Co grew its holdings in Thermo Fisher Scientific by 38.1% during the first quarter. Pennsylvania Trust Co now owns 58,862 shares of the medical research company’s stock valued at $16,112,000 after purchasing an additional 16,246 shares during the period. Baxter Bros Inc. grew its holdings in Thermo Fisher Scientific by 2.2% during the first quarter. Baxter Bros Inc. now owns 29,600 shares of the medical research company’s stock valued at $8,102,000 after purchasing an additional 630 shares during the period. Finally, Winslow Evans & Crocker Inc. grew its holdings in Thermo Fisher Scientific by 2.8% during the first quarter. Winslow Evans & Crocker Inc. now owns 17,298 shares of the medical research company’s stock valued at $4,736,000 after purchasing an additional 470 shares during the period. 89.24% of the stock is owned by institutional investors.

Shares of TMO stock traded up $1.26 during trading on Wednesday, reaching $277.46. The company’s stock had a trading volume of 168,999 shares, compared to its average volume of 1,574,825. The business has a fifty day moving average price of $285.71 and a 200-day moving average price of $272.38. The company has a quick ratio of 1.07, a current ratio of 1.49 and a debt-to-equity ratio of 0.58. The company has a market cap of $110.59 billion, a price-to-earnings ratio of 24.95, a price-to-earnings-growth ratio of 1.81 and a beta of 1.11. Thermo Fisher Scientific Inc. has a one year low of $208.34 and a one year high of $305.45.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 24th. The medical research company reported $3.04 EPS for the quarter, topping the Zacks’ consensus estimate of $3.01 by $0.03. The business had revenue of $6.32 billion for the quarter, compared to analyst estimates of $6.31 billion. Thermo Fisher Scientific had a net margin of 14.24% and a return on equity of 17.11%. The firm’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.75 earnings per share. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 12.24 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Tuesday, September 17th will be given a $0.19 dividend. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.27%. The ex-dividend date of this dividend is Monday, September 16th. Thermo Fisher Scientific’s dividend payout ratio is presently 6.83%.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 50,000 shares of the company’s stock in a transaction on Tuesday, July 30th. The shares were sold at an average price of $284.83, for a total transaction of $14,241,500.00. Following the sale, the chief executive officer now directly owns 342,193 shares of the company’s stock, valued at $97,466,832.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director C Martin Harris sold 275 shares of the company’s stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $270.73, for a total transaction of $74,450.75. Following the sale, the director now directly owns 6,433 shares in the company, valued at $1,741,606.09. The disclosure for this sale can be found here. In the last three months, insiders sold 52,775 shares of company stock worth $14,986,676. 0.45% of the stock is currently owned by insiders.

A number of research analysts recently issued reports on the stock. Needham & Company LLC boosted their price objective on shares of Thermo Fisher Scientific from $315.00 to $321.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Wolfe Research started coverage on shares of Thermo Fisher Scientific in a research note on Thursday, May 30th. They issued an “outperform” rating on the stock. Credit Suisse Group reaffirmed a “buy” rating and issued a $310.00 price target on shares of Thermo Fisher Scientific in a research note on Wednesday, July 31st. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $299.00 price target on the stock in a research note on Wednesday, June 12th. Finally, Argus lifted their price target on shares of Thermo Fisher Scientific from $285.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, May 1st. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Thermo Fisher Scientific currently has a consensus rating of “Buy” and an average price target of $303.17.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Read More: Cryptocurrencies

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.